A phase Ib/II study of AZD0120, dual-targeting autologous chimeric antigen receptor T-cell (CAR T) therapy directed against CD19 and B-cell maturation antigen (BCMA) in participants with relapsed/refractory multiple myeloma

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today